还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

0 s+ Q0 |2 w- S9 P                               
登录/注册后可看大图

# ^8 r' Y  L- l0 n" }( O  Q. o3 C请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

# O# \+ g" I# x! a5 i可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


Sub-category:
5 S. C# x$ Y: e( f& ^! xMolecular Targets


% _7 J8 t: x7 E! Z% _( gCategory:
* q3 R8 u/ U5 P# R: t! mTumor Biology

, T5 z" B/ }5 e5 |! Q1 l$ d
; ?8 e5 P5 g. \8 T; HMeeting:
( Z& ~0 I. c% j' }  o9 n* g& q2 B3 l2011 ASCO Annual Meeting


2 F( J& A5 g5 ~0 RSession Type and Session Title:
$ Y, |7 `$ E+ i* \Poster Discussion Session, Tumor Biology

; v/ [( `  h  @2 K8 H, e
/ K6 i/ f0 X5 w2 ZAbstract No:
# d# ^6 K9 X% W0 Y+ a1 K10517
  `, Z- K# ~6 ]6 y
9 s% D& k! r) o( a+ D
Citation:
9 }& V; i+ m* D5 ^J Clin Oncol 29: 2011 (suppl; abstr 10517)
1 I% u# z5 B. G" I; s- _% e  }

Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
. n* n7 S9 d$ T/ f  d  G4 I

/ S' U+ x5 ^" _0 g: `' W
, i7 W  A* S, y  e( C5 RAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
' s9 n) @" F0 v7 ?7 g1 G, P
Abstract Disclosures

4 k2 R* I" b1 }' hAbstract:
* X2 J& p# Z* l7 u. z6 d( B8 B5 o( Y

: g* I$ z7 m7 e& O! O# ^8 bBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

) `, Y& q4 |! v# _) s6 X. j' h9 x

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

1 }& K% {8 s" L. [5 {! G没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

3 Q3 a4 [& `: u$ g, I5 s! @1 b+ k化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

9 P  C4 [2 g. t平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
2 q: n5 H( n5 D/ ]
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊